ACUITY-PCI: one drug does not fit all

Lancet

Volumn 369, Issue 9565, 2007, Pages 881-882

  Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR; HEPARIN; HIRULOG;

ACUTE CATHETERIZATION AND URGENT INTERVENTION TRIAGE STRATEGY; ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; COST; DRUG EFFICACY; DRUG SAFETY; EMERGENCY HEALTH SERVICE; HUMAN; ISCHEMIA; MONOTHERAPY; PRIORITY JOURNAL;

EID: 33947174704     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60421-8     Document Type: Note

References (7)

1. Stone G., White H., Ohman E., et al., for the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 369 (2007) 907-919
2. Stone G., McLaurin B., Cox D., et al., for the ACUITY investigators. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
3. Lincoff A., Bittl J., Harrington R., et al., for the REPLACE-2 investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
4. White H., Kleiman N., Mahaffey K., et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 152 (2006) 1042-1050
5. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 354 (2006) 1464-1476
6. Kinnaird T., Stabile E., Mintz G., et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92 (2003) 930-935
7. Boersma E., Akkerhuis K., Theroux P., Califf R., Topol E., and Simoons M. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 100 (1999) 2045-2048